Richard D Carvajal et al.
JAMA, 311(23), 2397-2405 (2014-06-19)
Uveal melanoma is characterized by mutations in GNAQ and GNA11, resulting in mitogen-activated protein kinase pathway activation. To assess the efficacy of selumetinib, a selective, non-adenosine triphosphate competitive inhibitor of MEK1 and MEK2, in uveal melanoma. Randomized, open-label, phase 2